


Accepted Manuscript

Chagas disease knocks on our door: A cross-sectional study among latin american immigrants in milan, italy

Spinello Antinori, Laura Galimberti, Romualdo Grande, Roberto Bianco, Letizia Oreni, Letizia Traversi, Davide Ricaboni, Giovanna Bestetti, Alessia Lai, Davide Mileto, Maria Rita Gismondo, Marina Petullà, Silvia Garelli, Gianfranco De Maio, Chiara Cogliati, Daniela Torzillo, Anna Maria Villa, Ada Maristella Egidi, Ernestina Carla Repetto, Anna Lisa Ridolfo, Mario Corbellino, Massimo Galli



PII: S1198-743X(18)30227-1

DOI: [10.1016/j.cmi.2018.03.017](https://doi.org/10.1016/j.cmi.2018.03.017)

Reference: CMI 1248

To appear in: *Clinical Microbiology and Infection*

Received Date: 2 December 2017

Revised Date: 5 March 2018

Accepted Date: 8 March 2018

Please cite this article as: Antinori S, Galimberti L, Grande R, Bianco R, Oreni L, Traversi L, Ricaboni D, Bestetti G, Lai A, Mileto D, Gismondo MR, Petullà M, Garelli S, De Maio G, Cogliati C, Torzillo D, Villa AM, Egidi AM, Repetto EC, Ridolfo AL, Corbellino M, Galli M, Chagas disease knocks on our door: A cross-sectional study among latin american immigrants in milan, italy, *Clinical Microbiology and Infection* (2018), doi: 10.1016/j.cmi.2018.03.017.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**CHAGAS DISEASE KNOCKS ON OUR DOOR: A CROSS-SECTIONAL STUDY AMONG
LATIN AMERICAN IMMIGRANTS IN MILAN, ITALY**

Spinello Antinori^{1,2}, Laura Galimberti², Romualdo Grande³, Roberto Bianco⁴, Letizia Oreni²,
Letizia Traversi², Davide Ricaboni², Giovanna Bestetti², Alessia Lai¹, Davide Mileto³, Maria Rita
Gismondo³, Marina Petullà⁴, Silvia Garelli⁵, Gianfranco De Maio⁵, Chiara Cogliati⁶, Daniela
Torzillo⁶, Anna Maria Villa⁷, Ada Maristella Egidi⁵, Ernestina Carla Repetto⁵, Anna Lisa Ridolfo²,
Mario Corbellino², Massimo Galli^{1,2}

¹ Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy; ²III
Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy; ³
Laboratory of Clinical Microbiology, Virology and Bioemergency, ASST Fatebenefratelli Sacco,
Milan, Luigi Sacco Hospital, Italy; ⁴Radiology Unit, ASST Fatebenefratelli Sacco, Luigi Sacco
Hospital, Milan, Italy; ⁵II Division of Internal Medicine, ASST Fatebenefratelli Sacco, Milan,
Italy; ⁶Médecins San Frontières, Medical Department, Operational Centre Brussels, MSF-Italy,
Rome, Italy; ⁷Opera San Francesco per i Poveri, Milan, Italy.

RUNNING TITLE: Chagas disease in Italy

Correspondence to:

Prof. Spinello Antinori

Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan

Via GB Grassi 74,

20157 Milano, Italy

Tel. +390250319765; Fax +390250319758; E-mail: spinello.antinori@unimi.it

Abstract length : 249 words

Manuscript length : 2700 words

Figure: 1

Tables: 4

ABSTRACT

Objectives: We aimed to assess the prevalence and risk factors for Chagas Disease (CD) in Latin American immigrants and to evaluate the accuracy of diagnostic tests. Moreover, we offered to all positive subjects a complete free-of-charge clinical/instrumental evaluation as well as benznidazole treatment in order to stage the disease and verify drug tolerability.

Methods: A cross-sectional survey of CD among Latin Americans living in Milan and its metropolitan area was conducted between July 2013 and July 2014. Blood samples were tested for serologic evidence of CD together with a questionnaire covering demographic and clinical-epidemiological information.

Results: Forty-eight (9.6%) of the 501 tested subjects were conclusively diagnosed as having CD. The highest prevalence of CD was among those from Bolivia (43/169, 25.4%) and El Salvador (4/68, 5.9%). Older age (adjusted odds ratio [aOR] 1.05, $p=0.004$), a Bolivian origin (aOR 8.80; $p=0.003$), being born in the department of Santa Cruz (aOR 3.72, $p=0.047$), having lived in mud houses (aOR 2.68; $p=0.019$), and having an affected relative (aOR 12.77, $p=0.001$) were independently associated with CD. The ARCHITECT Chagas test showed the highest sensitivity (100%) and specificity (99.8%). Twenty-nine of the subjects with CD (60.4%) underwent disease staging, ten of whom (35.7%) showed cardiac and/or digestive involvement. Benznidazole treatment was associated with high frequency of adverse reactions (19/27, 70.4%) and permanent discontinuation (8/27, 29.6%)

Conclusions CD is highly prevalent among Bolivians and Salvadorans living in Milan. Regions with a large Latin American immigrant population should implement programmes of active detection and treatment.

KEY WORDS: *Trypanosoma cruzi*; screening; Chagas disease; Latin American immigrants; Italy

INTRODUCTION

Chagas disease (CD) or American trypanosomiasis, which is caused by *Trypanosoma cruzi*, is a predominantly vector-borne parasitic zoonosis that, under ecological conditions is endemic in Central and South America, Mexico and Texas [1,2]. However, it can also be transmitted by oral route, blood transfusions, organ transplantations, and from mother to child [3], with the last three modes of transmission being a matter of concern in non-endemic countries. The World Health Organisation (WHO) estimates that about six million people are infected by *T. cruzi* throughout the world, 62% of whom live in countries of the Southern Cone initiative against CD, particularly Argentina, Brazil, Bolivia and Mexico [4].

Over the last 10-15 years, massive migration from Latin America to Europe and the USA has led to the urbanisation of CD in non-endemic countries, and a recent meta-analysis of studies of CD among Latin Americans living in the European Union (EU) has calculated a pooled prevalence of 4.2% [5]. Like Spain, Italy hosts many people who have immigrated to the EU but, despite this, the disease is largely unknown to Italian physicians, which has led to a call to “break this epidemiological silence” [6-9].

The aims of this study were: 1) to assess the prevalence and risk factors for *T. cruzi* infection in a population of Latin American living in Milan and its metropolitan area; 2) to compare the overall accuracy of serological methods to detect *T. cruzi* infection; 3) to define the clinical stage of the disease among infected patients; and 4) to evaluate benznidazole tolerability among treated patients.

METHODS

Study design and setting

This cross-sectional survey of CD was conducted in a population of Latin American (LA) subjects living in Milan and its metropolitan area (which hosts the largest LA community in Italy) [10] between 30 July 2013 and 30 July 2014. The top 5 countries of origin for this population are Brazil, Bolivia, Ecuador, El Salvador and Peru (Fig.1). The participants were recruited by means of an active outreach to the local Latino communities with the support of Médecins Sans Frontières

(MSF): three MSF health promoters of LA origin participated in 20 health fairs in 13 sites including local churches (n= 8) cultural community organizations (n=5) and the Bolivian consulate (n=1).

Screening sessions took place 2-3 times monthly in a dedicated outpatient clinic at our Hospital and at “Opera San Francesco per i Poveri”, an outpatient care facility for indigent subjects and undocumented immigrants.

Demographic and clinic-epidemiological information was collected at the time of blood sampling using a standardised questionnaire. The study protocol also included serological testing for *Strongyloides*. Free clinical investigations and treatment were offered to all of the subjects diagnosed as having CD.

The study was approved by the Ethics Committee of AO-Polo Universitario Luigi Sacco, Milan, Italy (Protocol No. 480/2013/61/AP) and the Médecins San Frontières Ethics Review Board (Geneva, Switzerland). Written informed consent was obtained for subjects before their enrolment (in the case of children, this was given by their parents/guardians).

Laboratory methods

CD screening was carried using two serological tests in parallel: an enzyme-linked immunosorbent assay (ELISA) based on a lysate antigen of *T. cruzi* (BioELISA Chagas III, BiosChile, Santiago, Chile) and a chemiluminescence immunoassay (CLIA) based on recombinant antigens of distinct regions of the parasite (ARCHITECT Chagas, Abbott, Chicago, IL, USA), which was performed using an automated ARCHITECT i2000_{SR} system (Abbott).

A subset of blood samples were also tested by means of a CLIA directed against three distinct antigenic regions (LIASON® XL MUREX Chagas, DiaSorin, Saluggia, Italy) and an immunochromatographic test (*Trypanosoma cruzi* IgG Rapid Test, ImmunoSpark, SD, Rome, Italy) in order to investigate their performance in screening CD. Serological testing for anti-*Strongyloides stercoralis* IgG was carried out using the *Strongyloides ratti* ELISA (Bordier Affinity Products, Effegiemme Diagnostici, Milan, Italy).

CD diagnosis and treatment

CD was diagnosed on the basis of the concordant positive results of two independent serological tests in accordance with the WHO guidelines [11].

Cardiac involvement was investigated by means of electrocardiography (ECG), chest X-rays, and echocardiography. The Brazilian Consensus Classification was used to classify cardiac CD [12].

Digestive involvement was assessed by means of a colonic barium enema and a barium X-ray of the esophagus and considered pathological as previously reported [13,14].

All of the CD-positive participants were offered treatment with benznidazole 5 mg/kg/day (maximum 300 mg/day) for 60 days.

Statistical analysis

The continuous variables were compared using the Mann-Whitney non-parametric test; the categorical variables were compared using the chi-squared test, with Fisher's corrections when necessary. Univariate and multivariate logistic regression models were used to identify the factors associated with CD. The variables in the multivariate analysis were selected using a backward procedure based on a cut-off p -value of 0.05.

The diagnostic accuracy of serological test was calculated as sensitivity, specificity, validity index, positive and negative predictive values (PPV and NPV), positive and negative likelihood ratio and the Youden index, which is a measure of the overall discriminative power of a diagnostic procedure and Cohen's kappa coefficient which describes the level of concordance among tests.

RESULTS

A total of 501 Latin Americans (63% female) were screened for CD: 471 adults with a median age of 39 years (interquartile range [IQR] 32.0-48.7), and 30 children with a median age of 10.5 years (IQR 8.2-14.0), of whom seven were born in Latin America and had been adopted by Italians, and five were born in Italy of Latin American parents. The median time from their arrival in Italy was eight years (IQR 3.5-11.0). Ninety-one percent of the subjects came from four countries (Bolivia, Peru, El Salvador, Ecuador); the others came from Brazil (16), Argentina (6), Venezuela (4), Chile

(3), Colombia (3), Guatemala (2), Paraguay (2) and Uruguay (1), or had no recorded country of origin (8).

Serology diagnosis

Initially 46 subjects (9.2%) were diagnosed with *T. cruzi* infection on the basis of two concordant serology results; 451 subjects (90.0%) had negative serology with both tests and 4 (0.8%) had initially discordant results: three positive with ARCHITECT (2.87, 4.69 and 1.21 S/CO, respectively) and negative with BioELISA (0.03, 0.7 and 0.22 index value, respectively) and one negative with ARCHITECT (0.61 S/CO) and positive with BioELISA (1.2 index value). Repeated serology of discordant cases (using also the other available tests) allowed us to resolve the discrepancies with two confirmed cases (both with the highest S/CO on ARCHITECT and one of whom had a subsequent diagnosis of megacolon) and two negative cases.

In table 1 are summarised the diagnostic results and performance of serological and immunochromatographic assays used for the diagnosis of *T. cruzi* infection. A high proportion of patients were correctly classified by ARCHITECT and BioELISA (validity index 99.80 and 99.40, respectively) and both tests showed a high level of agreement (k index 0.955) although the former performed better for all measures. The Liaison Chagas assay has a high sensitivity and specificity but was slightly less efficient than the counterpart assay employing the chemiluminescence detection system. The median S/CO values were 13.8 (IQR 10.6-14.9) for the ARCHITECT assay and 11 (IQR 7.6-12) for the Liaison assay. With reference to true positive serum values, 43/48 samples (89.6%) showed results of > 6 S/CO with the ARCHITECT and 25/31 samples (80.6%) with the Liaison.

The performance of the rapid diagnostic test was characterised by low sensitivity (89% and a validity index of 91.6%

Prevalence of CD and risk factors for the disease

CD was diagnosed in 48 subjects (overall prevalence: 9.6%) of whom 43 coming from Bolivia (25.4% of the 169 enrolled Bolivians), four from El Salvador (5.9% of the 68 enrolled

Salvadorans), and one from Argentina. Bolivians accounted for 89.6% (43/48) of the subjects with CD and only 27.8% (126/453) of those without CD ($p<0.0001$). Subjects with CD came more frequently from the departments of Santa Cruz (24/48, 50% vs 47/453, 10.4%) and Cochabamba (15/48, 31.3% vs 43/453, 9.5%; $p<0.0001$); had more frequently lived in rural areas (39/48, 81.3% vs 233/453, 51.4%; $p=0.0001$) and mud houses (38/48, 79.1% vs 201/453, 44.3%; $p<0.0001$); were more frequently related to people affected by CD (11/48, 22.9% vs 5/453, 1.1%; $p<0.0001$); and were more frequently infected with *S. stercoralis* (7/48, 14.6% vs 18/453, 4.0%; $p=0.001$) (Tab. 2). Serology for *S. stercoralis* was positive in 5% of screened individuals (25/501), seventeen of whom from Bolivia, 3 from El Salvador, 2 from Peru and 1 from Brazil. Median serology titres were 1.47 (IQR 1.15-1.95). All patients with CD and strongyloidiasis were from Bolivia. Four out of 14 patients who underwent culture tested positive for *S. stercoralis*.

The results of the multivariate analysis (Tab.3) showed that the factors independently associated with an increased risk of developing CD were an older age (aOR: 1.05 for every year older, 95% CI 1.02-1.09; $p=0.004$), Bolivian nationality (aOR 8.80, 95% CI 2.10-36.87; $p=0.003$), being born in the department of Santa Cruz (OR 3.72, 95% CI 1.02-13.64; $p=0.047$), having lived in a mud house (OR 2.68, 95% CI 1.17-6.13; $p=0.019$), and having a relative with a diagnosis of *T. cruzi* infection (OR 12.77, 95% CI 2.96-55.06; $p=0.001$).

Staging and treatment of CD cases

Twenty-nine (60.4%) of the subjects diagnosed with CD underwent clinical evaluations. On the basis of the findings of instrumental examinations, 17 subjects (58.6%) were classified as having indeterminate CD, four (13.8%) Chagas cardiomyopathy (Cc), five (17.2%) digestive Chagas disease, and one Cc + digestive disease (Tab. 4). Only two of these patients were symptomatic: one complained of palpitations and one of constipation. Twenty-seven of the 29 patients accepted benznidazole treatment. Nineteen (70.4%) experienced adverse reactions, which led to permanent treatment discontinuation in eight cases (29.6%): 4 women (4/19, 21%) and 4 men (4/8, 50%). The most frequent side-effects were skin rash (37%), pruritus (18.5%) and fever (14.8%). Two patients

had severe polyarthritis (7.4%) requiring hospitalisation, and two complained of severe arthralgias. Nervous system disturbances (headache, anxiety, dysgeusia and paresthesia) were recorded in five patients (18.5%).

DISCUSSION

This is the first survey of CD among Latin Americans living in the metropolitan area of Milan which hosts the largest community of LA immigrants in Italy. Previous retrospective studies carried in Italy have reported CD prevalence rates ranging from 4.2% to 17% [7,9], and one cross-sectional study recorded a prevalence of 7.9% [15]. In line with these data, the prevalence of *T. cruzi* infection in our population as a whole was 9.6%, being much higher (25.6%) among Bolivians, a finding that is similar to previous studies carried out in Italy, Spain and Switzerland [7-9,15-17]. In a meta-analysis by Requena-Méndez *et al.*, the pooled prevalence of *T. cruzi* infection among Bolivians living in Europe was 18.1% [5], which is three times higher than that estimated in Bolivia by the WHO (6.1%) [4].

We found that Bolivian nationality was associated with a 8.8 higher risk of testing positive for *T. cruzi*, which may reflect the fact that many of these people came from areas in which *T. cruzi* is hyperendemic [8,9,16,17]. Immigrants from Santa Cruz accounted for 42% of our Bolivian population, and being born there was associated with a three times higher risk of developing CD in comparison with other Latin American localities outside Bolivia.

It should also be noted that the prevalence of CD among immigrants from El Salvador was as high as 5.9%. According to WHO estimates, El Salvador is fifth most affected Latin American country, with a prevalence of 1.3% [4]. However, two recent studies of pregnant women and blood donors living in the departments of Sonsonate and Ahuachapàn found prevalence rates of respectively 3.8% and 2.5% [18,19], and it has been reported that the prevalence of CD among Salvadoran immigrants living in Los Angeles is 3.4% [20]. There is little information about the prevalence of CD among

Salvadorans living in Europe: the above mentioned meta-analysis [5] that included 67 Salvadoran migrants found a pooled prevalence of 3.7%: three times that estimated in El Salvador by the WHO [4].

Our findings also show that, regardless of nationality and department of origin, an older age is associated with an increased risk for CD, which probably reflects longer and more intense exposure to vector transmission in the country of origin [17] as none of the children in our study had CD. As expected, having lived in a mud house and having a relative with CD were also independently associated with an increased risk of CD [8,21,22]. The significant higher prevalence of strongyloidiasis observed among patients with CD confirms the results of a recent retrospective Spanish study highlighting possible shared epidemiologic and socioeconomical risk factors and the need of a combined screening for both infections [23].

CD diagnosis based on simultaneous use of two serological tests is costly and time consuming. Moreover, even with this expedient a discordance between tests can be observed. In our study, a discordance was observed in the 0.8% of cases but this rate was much higher (3.3%) in a recent Spanish-Italian study [24]. Repeating the tests on a new serum sample can usually solve much of discordant cases but for those with still inconclusive results it is indicated to employ a western blotting directed toward trypomastigote excreted-secreted antigens (TESA). On the other hand there is increasing need to make serology screening for CD simpler, faster and cheaper possibly using a single test. In this regard Abras *et al.* proposed the use of ARCHITECT Chagas as a single technique for routine screening based on its high sensitivity and specificity [25]. We observed a high level of agreement between the two different serological tests employed in our study but we confirm that ARCHITECT Chagas had the best performance (100% sensitivity , 99.8% specificity) and we concur with the strategy suggested by Abras *et al.* to reserve a second test only for positive sera with a result < 6 S/CO that in our study were about 10% [25].

Previous studies have shown that the sensitivity of rapid diagnostic tests is unacceptable for screening purposes [26,27], and our own experience with the ImmunoSpark assay resulted unsatisfactory (validity index 91.6%).

More than one-third of our patients with CD showed organ involvement, with digestive disease being the most frequent (17.2%). This is consistent with the findings of two Italian studies [8,9], and suggests that digestive CD may be more frequent in Italy than in Spain or Switzerland [17,21,22,28]. This may be due to differences in the origins of the study populations and the disease classification criteria (inclusion of dolichocolon) [8], which may lead to the over-diagnosis of digestive CD [29]. However, even excluding people with dolichocolon, the 10.3% frequency of megacolon in almost all of our asymptomatic subjects is higher than that reported in other studies of patients complaining of digestive symptoms [17,21], thus supporting the importance of radiographic evaluation of all patients testing positive for CD. Conversely, we did not detect any abnormalities in the esophagus X-ray in our asymptomatic subjects, which argues against the usefulness of systematic esophageal assessments suggested by some authors [8,21].

The efficacy of benznidazole in the treatment of chronic CD is still debated, particularly its ability to slow the progression of Chagas cardiomyopathy [30,31]. A considerable proportion (70%) of our patients experienced adverse drug reactions (mainly skin rash) and about one-third permanently discontinued treatment a rate similar to that observed in studies carried out in non-endemic countries, but higher than that reported in endemic countries [31-34]. It remains to be established whether this reflects European physicians' lack of confidence and experience in treating CD, or other reasons such as the gender composition of the study population [33].

We acknowledge that our study has several limitations. Firstly, individuals who came to make the screening may be not representative of the whole population of LA immigrants living in our metropolitan area and might have been more motivated by perceiving themselves at risk of CD and thus our results can overestimate the true prevalence of the infection, a selection bias observed also

in other studies conducted in Europe [5,35]. Secondly, our results may not be generalizable to other European countries or Italian regions.

In conclusion, CD is highly prevalent among Bolivians and Salvadorans and therefore regions with large LA immigrant communities, such as ours, should implement programmes aimed at actively detecting and treating CD with particular attention to special population such as pregnant women and immunocompromised patients.

Figure legend

Figure 1. Countries of origin and number of people living in Milan and its metropolitan area (overall) in 2014 for the five more represented communities of Latin American immigrants (Ref.10)

Acknowledgements

We would like to thank all of our nursing staff who collected the blood samples, and the students at the University of Milan's Post-graduate School of Infectious and Tropical Diseases who took part in administering the questionnaire. We are also grateful to Dr. Andrea Angheben for his advice on the management of CD. Finally we are grateful to the MSF Health promoters especially Ahmad Al Rousan and Dr Pierfranco Olivani (NAGA)

Trasparency declaration

The Authors declare that they have nothing to disclose regarding conflict of interests with respect to this manuscript. The Medical Operational Support Team of Rome (MOSTRo) of Médecins Sans Frontières provided the funds to acquire the ARCHITECT and BiosChile assays and the study was also partly funded by the "Piano Sostegno alla Ricerca-UniMI 2015-2017.

REFERENCES

1. Pereira Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL on behalf of the Council on Chagas Disease of the International Society of cardiology. Chagas disease. An overview of clinical and epidemiological aspects. *J Am Coll Cardiol* 2013; 62:767-76.
2. Garcia MN, Aguilar D, Gorchakov R, Rossmann SN, Montgomery SP, Rivera H et al. Evidence of autochthonous Chagas disease in southeastern Texas. *Am J Trop Med Hyg* 2015;92:325-30.
3. Perez Molina JA, Martinez Perez A, Norman FF, Monge-Mailla B, Lopez Velez R. Old and new challenges in Chagas disease. *Lancet Infect Dis* 2015; 15:1347-56.
4. World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. *Wkly Epidemiol Rec* 2015; 90:33-44.
5. Requena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. *Plos Negl Trop Dis* 2015; 9:e0003540.
6. Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, et al. Working Group on Chagas Disease. Chagas disease in European countries: the challenge of a surveillance system. *Euro Surveill* 2011; 16:pii:19968.
7. Angheben A, Anselmi M, Gobbi F, Marocco S, Monteiro G, Buonfrate D, et al. Chagas disease in Italy: breaking an epidemiological silence. *Euro Surveill* 2011;16:pii=19969.
8. Gobbi F, Angheben A, Anselmi M, Postiglione C, Repetto E, Buonfrate D, et al. Profile of *Trypanosoma cruzi* infection in a Tropical medicine Reference Center, Northern Italy. *Plos Negl Trop Dis* 2014; 8:e3361.
9. Repetto EC, Zachariah R, Kumar A, Angheben A, Gobbi F, Anselmi M, et al. Neglect of a neglected disease in Italy: the challenge of access-to-care for Chagas disease in Bergamo area. *Plos Negl Trop Dis* 2015;9:e0004103.
10. Cittadini stranieri in Italia-2014. <https://www.tuttitalia.it/lombardia/provincia-di-milano/statistiche/cittadini-stranieri/>

11. WHO Technical report series, 905. Control of Chagas disease: second report of the WHO expert committee. Geneva 2002.
12. Dias JC, Ramos AN Jr, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et al. 2nd Brazilian Consensus on Chagas Disease, 2015. *Rev Soc Bras Med Trop* 2016;49 (Suppl.1):3-60.
13. Ximenes CA. Técnica amplificada para o diagnóstico radiológico do megacolon chagásico. *Rev Bras Med Trop* 1984; 17:23.
14. de Rezende J, Lauer KM, de Oliveira A. Clinical and radiological aspects of aperistalsis of the esophagus. *Rev Bras Gastroenterol* 1960;12:247-62.
15. Di Girolamo C, Martelli G, Ciannamè A, Vocale C, Fini M, Stefanini A, et al. Chagas disease in a non-endemic country: a multidisciplinary research, Bologna, Italy. *J Immigrant Minority Health* 2016;18:616-23.
16. Navarro M, Perez-Ayala A, Guionnet A, Perez-Molina JA, Navaza B, Estevez L, et al. Targeted screening and health education for Chagas disease tailored to at-risk migrants in Spain, 2007 to 2010. *Euro Surveill* 2011; 16:pii=19973.
17. Jackson Y, Gétaz L, Wolff H, Holst M, Mauris A, Tardin A, et al. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. *Plos Negl Trop Dis* 2010;4:e592.
18. Sasagawa E, Guevara de Aguilar AV, Hernandez de Ramirez MA, Romero Chévez JE, Nakagawa J, Cedillos RA, et al. Prevalence of *Trypanosoma cruzi* infection in blood donors in El Salvador between 2001 and 2011. *J Infect Dev Ctries* 2014;8:1029-36.
19. Sasagawa E, Guevara de Aguilar AV, Hernandez de Ramirez MA, Chévez JE, Nakagawa J, Cedillos RA, et al. Acute Chagas disease in El Salvador 2000-2012- Need for surveillance and control. *Mem Inst Oswaldo Cruz* 2014;109:256-8.

20. Meymandi SK, Forsyth CJ, Soverow J, Hernandez S, Sanchez D, Montgomery SP, et al. Prevalence of Chagas disease in the Latin American-born population of Los Angeles. *Clin Infect Dis* 2017;64:1182-88.
21. Munoz J, Gomez I Prat J, Gallego M, Gimeno F, Treviño B, López-Chejade P, et al. Clinical profile of *Trypanosoma cruzi* in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). *Acta Trop* 2009;111:51-55.
22. Roca C, Pinazo MJ, Lopez-Chejade P, Bayó J, Posada E, López-Solana J, et al. Chagas disease among the Latin American adult population attending in a primary care center in Barcelona, Spain. *Plos Negl Trop Dis* 2011;5:e1135.
23. Puerta-Alcalde P, Gomez-Junyent J, Requena-Mendez A, Pinazo MJ, Alvarez-Martinez MJ, Rodriguez N, et al. High prevalence of *S. Stercoralis* infection among patients with Chagas disease: a retrospective case-control study. *Plos Negl Trop Dis* 2018;12(1):e0006199.
24. Moure Z, Angheben A, Molina I, Gobbi F, Espasa M, Anselmi M, et al. Serodiscordance in chronic Chagas disease diagnosis: a real problem in non-endemic countries. *Clin Microbiol Infect* 2016;22:788-92.
25. Abras A, Gallego M, Llovet T, Tebar S, Herrero M, Berenguer P, et al. Serological diagnosis of chronic Chagas disease: is it time for a change? *J Clin Microbiol* 2016;54:1566-72.
26. Flores-Chavez M, Cruz I, Nieto J, Gárate T, Navarro M, Pérez-Ayala A, et al. Sensitivity and specificity of an Operon immunochromatographic test in serum and whole-blood samples for the diagnosis of *Trypanosoma cruzi* infection in Spain, an area of nonendemicity. *Clin Vaccine Immunol* 2012;19:1353-59.
27. Angheben A, Staffolani S, Anselmi M, Tais S, Degani M, Gobbi F, et al. Accuracy of a rapid diagnostic test (Cypress Chagas Quick Test) for the diagnosis of chronic Chagas disease in a nonendemic area: a retrospective longitudinal study. *Am J Trop Med Hyg* 2017;97:1486-88.

28. Perez-Ayala A, Perez-Molina JA, Norman F, Navarro M, Monge-Maillo B, Diaz-Menendez M, et al. Chagas disease in Latin American migrants: a Spanish challenge. *Clin Microbiol Infect* 2011;17:1108-1113.
29. Pinazo MJ, Lacima G, Elizade JI, Posada EJ, Gimeno F, Aldasoro E, et al. Characterization of digestive involvement in patients with chronic *T. cruzi* infection in Barcelona. *Plos Negl Trop Dis* 2014;8:e3105.
30. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. *Ann Intern Med* 2006;144:724-34.
31. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. BENEFIT investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. *N Engl J Med* 2015;373:1295-306.
32. Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, Holanda MT, Silvestre de Sousa A, Sangenis LHC, et al. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease. *J Antimicrob Chemother* 2017;72:2596-2601.
33. Olivera MJ, Cucunuba ZM, Valencia-Hernandez CA, Herazo R, Agreda-Rudenko D, Flórez C, et al. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. *PLoS One* 2017; 12:e0185033.
34. Aldasoro E, Posada E, Requena-Mendez A, Calvo-Cano A, Serret N, Casellas A, et al. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. *J Antimicrob Chemother* 2018; Jan 16.doi:10.1093/jac/dkx516.
35. Connors EE, Vinetz JM, Weeks JR, Brouwer KC. A global systematic review of Chagas disease prevalence among migrants. *Acta Trop* 2016;156:68-78.

Table 1. Performance of four serological tests for the diagnosis of *T.cruzi* infection ^a.

Measure	ARCHITECT Chagas ^b (n=501)		BioELISA Chagas III ^c (n=501)		Chagas Liaison XL ^d (n=263)		Chagas Rapid ImmunoSpark ^e (n=95)	
	Number/total	95% CI	Number/total	95% CI	Number/total	95% CI	Number/total	95% CI
Sensitivity (%)	100 (49/49)	91.01-100	95.92 (47/49)	85.34-99.56	96.77 (30/31)	82.15-100	89.29 (25/28)	71.79-96.96
Specificity (%)	99.78 (451/452)	98.60-100	99.78 (451/452)	98.60-100	99.14 (230/232)	96.66-99.95	92.54 (62/67)	83.21-97.08
Validity index (%)	99.80 (500/501)	99.41-100	99.40 (498/501)	98.73-100	98.86 (260/263)	97.58-100	91.58 (87/95)	85.99-97.16
PPV (%)	98.00 (49/50)	94.12-100	97.92 (47/48)	93.88-100	93.75 (30/32)	85.36-100	83.33 (25/30)	70.00-96.67
NPV (%)	100 (451/451)	100-100	99.56 (451/453)	98.95-100	99.57 (230/231)	98.72-100	95.38 (62/65)	90.28-100
LR+	452.00	63.81-3201.83	433.55	61.15-3073.76	112.26	28.20-446.85	11.96	5.10-28.07
LR-	0.00	-	0.04	0.01-0.16	0.03	0.00-0.22	0.12	0.04-0.34
Youden's index	1.00	1.00-1.00	0.96	0.86-1.00	0.96	0.83-1.00	0.82	0.65-0.92

a- In case of discordant results serology was repeated using a new sample after 2-4 months.

b- The chemiluminescent reaction is measured in relative light units (RLUs). The results are expressed as sample RLUs/cutoff value (S/CO) with ratio < 0.8 considered negative, inconclusive from ≥ 0.8 to < 1 and ≥ 1 positive.

c- For the ELISA test results were expressed as the index between the absorbance of the test serum and the cutoff value. Tests were considered negative if the index was < 0.9, equivocal if ≥ 0.9 and < 1, and positive if ≥ 1 .

d- The chemiluminescent reaction is measured in relative light units (RLUs). The results are expressed as sample RLUs/cutoff value (S/CO) with ratio < 0.9 considered negative, inconclusive from ≥ 0.9 < 1 and ≥ 1 positive.

e - 5 μ L of serum were added in the sample port following the transfer of 2 full drops of conjugate into the reagent port. The results were read within 5 minutes after the sample application. The test was considered positive if a pink/purple line was seen in the test and control areas. The test was considered negative if a pink/purple line was seen only in the control area. The test was invalid (and was repeated) if the control line failed to appear.

PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR-: negative likelihood ratio. 95%CI, 95% confidence interval.

Table 2. Characteristics of the participants who were positive and negative to *T. cruzii* screening.

Variable	Total screened N=501	Negative for CD (n=453)	Positive for CD (n=48)	P value
Age in years, median (IQR)	39 (31-48)	39 (31-48)	41 (17-66)	0.405
Females	315 (62.9)	283 (62.5)	16 (33.3)	0.448
Males	186 (37.1)	170 (37.5)	32 (66.7)	
Country of origin, n (%)				
Bolivia	169 (33.7)	126 (27.8)	43 (89.6)	<0.0001
Peru	159 (31.8)	159 (35.1)	0 (0.0)	
El Salvador	68 (13.6)	64 (14.1)	4 (8.3)	
Ecuador	60 (12.0)	60 (13.2)	0 (0.0)	
Other	45 (9.0)	44 (9.7)	1 (2.1)	
Department of origin, n (%)				
Santa Cruz	71 (14.2)	47 (10.4)	24 (50.0)	<0.0001
Cochabamba	58 (11.6)	43 (9.5)	15 (31.3)	
La Paz	18 (3.6)	18 (4.0)	0 (0.0)	
Other	354 (70.7)	345 (76.2)	9 (18.7)	
Had lived in rural areas, n (%)				
Yes	272 (54.2)	233 (51.4)	39 (81.2)	0.0001
No	229 (45.7)	220 (48.6)	9 (18.7)	
Had lived in mud houses, n (%)				
Yes	239 (47.7)	201 (44.3)	38 (79.2)	<0.0001
No	262 (52.3)	252 (55.7)	10 (20.8)	
Had received transfusion, n (%)				
Yes	43 (8.6)	3 (6.3)	40 (8.8)	0.569
No	458 (91.4)	45 (93.7)	413 (91.2)	
Had a relative with CD, n (%)				
Yes	16 (3.2)	5 (1.1)	11 (22.9)	<0.0001
No	485 (96.8)	448 (98.9)	37 (77.1)	
Positive to <i>Strongyloides</i> serology, n (%)				0.001
Yes	25 (5.0)	18 (4.0)	7 (14.6)	
No	476 (95.0)	435 (96.0)	41 (85.4)	

Table 3- Univariate and multivariate logistic regression analysis of the risk factors for Chagas disease


	Univariate analysis			Multivariate analysis		
	OR	95% CI	<i>p</i> value	aOR	95% CI	P value
Age, for 1 year more	1.01	0.99-1.04	0.314	1.05	1.02-1.09	0.004
Gender						
Males	1					
Females	1.28	0.67-2.44	0.449	-	-	-
Country of origin						
All but Bolivia	1			1		
Bolivia	21.80	8.43-56.35	<0.0001	8.80	2.10-36.87	0.003
Department of origin						
Provinces outside Bolivia	1			1		
Santa Cruz	17.99	7.96-40.66	<0.0001	3.72	1.02-13.64	0.047
Cochabamba	12.96	5.42-30.96	<0.0001	2.09	0.56-7.78	0.272
La Paz	0.98	0.05-18.92	0.991	0.18	0.01-4.06	0.278
Having lived in rural areas						
No	1					
Yes	3.99	1.88-8.44	<0.001	-	-	-
Having lived in mud houses						
No	1			1		
Yes	4.64	2.25-9.56	<0.0001	2.68	1.17-6.13	0.019
Previous transfusions						
No	1					
Yes	0.70	0.21-2.37	0.571	-	-	-
Having a relative with CD						
No	1			1		
Yes	24.22	7.86-74.57	<0.0001	12.77	2.96-55.06	0.001
Serological positivity for <i>Strongyloides</i>						
No	1			1	-	-
Yes	4.23	1.67-10.73	0.002	12.77		

The strength of the associations was measured by means of odds ratios (ORs) and adjusted ORs (aORs) with their 95% confidence intervals (95% CI). All of the data were statistically analysed using SAS version 9.4, and differences with *p*-values of <0.05 were considered statistically significant.

Table 4- Clinical characteristics of 29 subjects with Chagas disease who underwent clinical staging.

Characteristic	N (%)
Country of origin	
Bolivia	26 (89.7)
El Salvador	2 (6.9)
Argentina	1 (3.4)
Median age (IQR)	37.5 (17-67)
Gender	
Male	7 (24.1)
Female	22 (75.9)
Clinical stage,	
Indeterminate	18 (62.1)
Chagas cardiomyopathy	4 (14.3)
Digestive Chagas	5 (17.8)
Chagas cardiomyopathy + digestive disease	1 (3.6)
ECG,	
Normal	22 (75.9)
RBBB*	2 (6.9)
Right focal BBB	1 (3.4)
Sinus bradycardia (< 50 bpm)	2 (6.9)
Sinus bradycardia+RBBB	1 (3.4)
IRBB§	1 (3.4)
Chest radiography	
Normal	27 (93.1)
Enlarged heart	1 (3.5)
Hilar lymphadenopathy‡	1 (3.5)
Echocardiography	
Normal ejection fraction (>50%)	29 (100)
Normal findings	12 (41.4)
Mild tricuspid regurgitation	7 (20.7)
Mild mitral regurgitation	5 (17.2)
Mild mitral and aortic regurgitation	1 (3.4)
Tricuspid insufficiency	2 (6.9)
Esophageal barium	
Normal	29 (100)
Barium enema	
Normal	22 (75.0)
Dolichocolon	4 (14.3)
Megacolon	3 (10.7)

*RBBB: right bundle branch block; §IRBB: incomplete right bundle-branch block; ‡ Confirmed to be sarcoidosis



ACCEPTED TEL